||Neonatal Drug Therapy Manual
Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.
RSV Immune Globulin, Synagis
Humanized Monoclonal Antibody
- Prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV, according to criteria for use
- IM: preferably in the anterolateral aspect of the thigh. The gluteal muscle should not be used routinely as an injection site because of the risk of damage to the sciatic nerve.
*Doses greater than 1 mL should be divided.
- 15 mg/kg/dose of body weight, every 30 days, throughout the RSV season
- First dose will be administered within 2 weeks prior to discharge from hospital
- Pain at injection site
- In most studies, the incidence of adverse effects has been comparable in the placebo and palivizumab groups
Parameters to Monitor:
- Observe infant for a possible allergic reaction
Reconstitution and Stability:
Palivizumab (RSV IG) 50 mg or 100 mg vial
- To be prepared by pharmacv
- Final concentration: 100 mg/mL
- Administer within 6 hours of dilution
The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.
CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.
Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.